Lords Mark Industries’ Renalyx Secures CDSCO Licence and CE Marking for AI-Based Hemodialysis Machines
Lords Mark Industries’ med-tech arm Renalyx has secured CDSCO approval to manufacture Class C hemodialysis machines in India, alongside CE certification for European markets, enabling domestic production and global distribution of high-risk dialysis equipment.
Lords Mark Microbiotech Gets NABL Accreditation
Following the development, the company has outlined a national expansion plan that includes setting up 200 laboratories and 2,000 collection centres over the next two years.
India Weighs Minimum Import Price as Antibiotic API Prices Fall Sharply
The recent drop in global prices has led to concerns that domestic facilities may face difficulty competing immediately after commissioning.
Sirolimus Drug-Eluting Balloon Presented as a Potential Alternative to Stents for Larger Arteries
MedAlliance’s SELUTION sirolimus drug-eluting balloon shows stent-comparable outcomes in a 3,300-patient trial, signalling a major shift toward stentless coronary interventions for global cardiology providers.
Lords Mark Industries Ltd. Secures US FDA Registration, Strengthens Global Healthcare Manufacturing Capabilities
Lords Mark Industries secures US FDA registration for its surgical and hygiene products, boosting India’s global healthcare manufacturing footprint with enhanced quality and compliance systems
Delius Pharma Reports 672.50% YoY Revenue Growth in Q1, Targets Rs 350 Crore Antibiotics Turnover by FY25
Delius Pharma posts 672.50% YoY Q1 growth, driven by antibiotics sales, API imports from China, new leadership, and Rs 70 crore plant investment; targets Rs 350 crore turnover by FY25-end.
Apollo Home Healthcare Launches Senior Geriatric Services in Navi Mumbai
The initiative offers seniors hospital evaluation with specialists, plus personalised recovery and long-term care at home – bridging the gap in India’s limited geriatric services.
Rainbow Children’s Medicare opens 100-bed hospital in Rajahmundry
RCML extended its network to 22 hospitals and five clinics in nine cities with the opening of its Rajahmundry unit. The 100-bed hospital houses NICU, PICU, high-risk obstetrics, and fertility services and caters to almost 10-12 million people in the area.
Eli Lilly’s Oral GLP-1 Pill Cuts 10.5% Weight in Diabetic Patients, Boosts Shares
Eli Lilly said on Tuesday its experimental GLP-1 pill helped overweight adults with type 2 diabetes shed 10.5% of body weight in a late-stage trial, after recent data from another study of the drug in patients without diabetes sent company shares tumbling.
Nova IVF Fertility Introduces AI for Embryo Selection in IVF Labs
Nova IVF Fertility has announced the adoption of Artificial Intelligence (AI) in its IVF laboratories through Vita Embryo, an AI-based embryo assessment technology developed by South Korea’s Kai Health.
ekincare Elevates Somak Ray to Co-founder Role for Global Growth
ekincare has elevated Somak Ray from Vice President – Operations to Co-founder, strengthening its leadership team as the company enters a phase of accelerated global expansion.
Rainbow Children’s Medicare to acquire majority stake in Guwahati’s Pratiksha Hospital for Rs. 171 crore
Rainbow Children’s Medicare Limited (RCML), a pediatric multi-speciality and perinatal care hospital chain in India, has signed a definitive agreement to acquire a majority stake in Pratiksha Hospital, Guwahati.
Vinay Prasad returns as the FDA’s top vaccine regulator just days after stepping down
Vinay Prasad is returning to his role overseeing vaccine, gene therapy and blood product regulation at the U.S. Food and Drug Administration a little more than a week after he left the agency.
Manipal Hospitals Moves to Acquire Sahyadri in Rs 6,400 Cr Deal, Awaits CCI Nod
Healthcare major Manipal Hospitals has sought approval from the fair trade regulator CCI to acquire Pune-based Sahyadri Hospitals from global investor Ontario Teachers' Pension Plan Board in a deal pegged at around Rs 6,400 crore.
US Tariffs on Indian Goods to Push Up Healthcare Costs, Warn Industry Experts
The US healthcare sector may face rising costs as a result of a 25% tariff and additional penalties on Indian imports, including pharmaceuticals and medical devices. Experts warn of declining profits, stalled R&D, and shifting global trade dynamics.
Empower your business. Get practical tips, market insights, and growth strategies delivered to your inbox
By continuing you agree to our Privacy Policy & Terms & Conditions
